JP2024536718A5 - - Google Patents
Info
- Publication number
- JP2024536718A5 JP2024536718A5 JP2024513990A JP2024513990A JP2024536718A5 JP 2024536718 A5 JP2024536718 A5 JP 2024536718A5 JP 2024513990 A JP2024513990 A JP 2024513990A JP 2024513990 A JP2024513990 A JP 2024513990A JP 2024536718 A5 JP2024536718 A5 JP 2024536718A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutically acceptable
- acceptable salt
- disease
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21194695 | 2021-09-03 | ||
| EP21194695.9 | 2021-09-03 | ||
| PCT/EP2022/074263 WO2023031311A1 (en) | 2021-09-03 | 2022-09-01 | Magl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536718A JP2024536718A (ja) | 2024-10-08 |
| JP2024536718A5 true JP2024536718A5 (enExample) | 2025-09-03 |
Family
ID=77640389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513990A Pending JP2024536718A (ja) | 2021-09-03 | 2022-09-01 | Ｍａｇｌ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240270725A1 (enExample) |
| EP (1) | EP4395840A1 (enExample) |
| JP (1) | JP2024536718A (enExample) |
| CN (1) | CN117836014A (enExample) |
| WO (1) | WO2023031311A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015099196A1 (en) * | 2013-12-26 | 2015-07-02 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
-
2022
- 2022-09-01 WO PCT/EP2022/074263 patent/WO2023031311A1/en not_active Ceased
- 2022-09-01 EP EP22772889.6A patent/EP4395840A1/en active Pending
- 2022-09-01 CN CN202280057420.6A patent/CN117836014A/zh active Pending
- 2022-09-01 JP JP2024513990A patent/JP2024536718A/ja active Pending
-
2024
- 2024-03-01 US US18/593,350 patent/US20240270725A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7066902B2 (ja) | 異常不随意運動障害の処置のための方法 | |
| JP6674903B2 (ja) | Ｓ１ｐ調節剤即時放出投与レジメン | |
| Doorduin et al. | [11C]-DPA-713 and [18F]-DPA-714 as new PET tracers for TSPO: a comparison with [11C]-(R)-PK11195 in a rat model of herpes encephalitis | |
| JP2020500862A5 (enExample) | ||
| RS62164B1 (sr) | Sulfoniluree i srodna jedinjenja i njihova upotreba | |
| JP2012525385A5 (enExample) | ||
| US10285981B2 (en) | Compositions and methods for treating amyotrophic lateral sclerosis in responders | |
| EP3253377B1 (en) | Monomethylfumarate prodrug compositions | |
| JP2013535437A5 (enExample) | ||
| JP2001511131A (ja) | 月経前不快障害の処置 | |
| CA2768587A1 (en) | Dp2 antagonist and uses thereof | |
| JP2021505575A (ja) | 非ラセミ混合物およびその使用 | |
| JP2002527474A (ja) | 躁病および双極性障害の治療法 | |
| SA07280161B1 (ar) | استخدام أجوميلاتين في الحصول على الأدوية المطلوبة لعلاج اضطراب القلق العام | |
| IL304577B2 (en) | Combination of thyroid hormones and an RXR agonist for the treatment of gastroenteritis | |
| JP2018039817A (ja) | 多発性硬化症を治療するためのＰＰＡＲγアゴニスト | |
| KR20160111013A (ko) | 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합 | |
| JP2022501383A5 (enExample) | ||
| JP7553728B2 (ja) | 高用量の放出調節フペルジン製剤の使用 | |
| JP2005524696A5 (enExample) | ||
| JP2023518640A5 (enExample) | ||
| EP3297621A1 (en) | A method for treating peripheral inflammatory disease | |
| JP5954737B2 (ja) | 放射性フッ素標識キノキサリン化合物 | |
| JP2023528895A5 (enExample) | ||
| US20200038349A1 (en) | Use of n-acetylcysteine amide in the treatment of penetrating head injury |